Unveiling the Global First, Seegene Presents an Unattended PCR Automation System, Revolutionizing Diagnostics at ADLM 2025 Conference.
The global diagnostics market is set for a significant shift, with Seegene Inc. unveiling its groundbreaking innovation, CURECATM, at ADLM 2025. This fully automated PCR testing system promises to streamline the entire testing process, from specimen storage to result analysis, with minimal human intervention [1][2][4].
At the heart of CURECATM is its complete automation of all PCR testing workflow steps, enabling unattended operation. This innovation minimizes human error and significantly improves the consistency and reliability of diagnostic results [1][2][4].
Seegene's proprietary high multiplex PCR technology is another key feature, allowing simultaneous detection of up to 14 pathogens with similar symptoms in a single test, enhancing diagnostic efficiency [1][3]. The system is designed to run continuously without breaks, enabling higher throughput and faster turnaround times [1][4].
The impact of CURECATM on laboratory operations and the diagnostics market is substantial. It dramatically increases testing efficiency and throughput by automating typically labor-intensive manual steps. By reducing reliance on skilled manual labor, it lowers the risk of human error, improving test accuracy and reliability [1][2].
CURECATM introduces a paradigm shift towards unattended, standardized testing workflows, potentially setting a new global gold standard for PCR diagnostics. It supports 24/7 operation, thus enabling laboratories to meet high testing demands efficiently [1][2].
Seegene is also pairing CURECATM with its STAgora™ big data platform to unify diagnostic data globally. This could transform diagnostics by improving data analytics and disease surveillance [1][2]. Pilot partnerships with selected institutions are underway to adopt this technology, indicating early market entry and potential for widespread adoption [1][2].
Seegene's syndromic real-time PCR technology, which forms the core of CURECATM, was particularly highlighted during the COVID-19 pandemic. The company provided over 340 million COVID-19 tests to more than 100 countries worldwide [5].
CURECATM's prep module is the first to fully automate pre-treatment processes across all major sample types, reducing labor demands, expanding sample throughput, and enhancing operational efficiency [6]. The prep module's applicability extends beyond PCR diagnostics, supporting pre-treatment for clinical chemistry and immunoassays [7].
In addition to CURECATM, Seegene's statistical platform, STAgoraTM, is expected to become an essential analytical tool for clinical decision-making. STAgoraTM collects and analyses data from hospitals worldwide, providing insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection [8]. It offers more than 40 statistical tools tailored for clinical support [9].
To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA [10]. Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene, stated that CURECATM and STAgoraTM represent a new global standard that will redefine diagnostics in clinical settings around the world [11].
In summary, Seegene’s CURECATM and STAgoraTM represent transformative innovations that automate and streamline PCR testing from start to finish, enhancing laboratory productivity, accuracy, and scalability while helping redefine diagnostic standards worldwide.
- The integration of Seegene's STAgora™ big data platform with CURECATM has the potential to revolutionize medical-conditions diagnostics, as it unifies global diagnostic data, improving disease surveillance and data analytics within the health-and-wellness sector.
- The technological advancements in CURECATM, such as its automation and high multiplex PCR technology, not only benefit the diagnostics market by increasing testing efficiency, but also extend its applications beyond PCR diagnostics, impacting clinical chemistry and immunoassays as well.
